Search

Your search keyword '"Alessandrino, Paolo"' showing total 15 results
Start Over Author "Alessandrino, Paolo" Search Limiters Available in Library Collection
15 results on '"Alessandrino, Paolo"'

1. A Modified Post-Transplant Cyclophosphamide Regimen, for Unmanipulated Haploidentical Marrow Transplantation, in Acute Myeloid Leukemia: A Multicenter Study

Author

Chiusolo, Patrizia, Bug, Gesine, Olivieri, Attilio, Brune, Mats, Mordini, Nicola, Alessandrino, Paolo Emilio, Dominietto, Alida, Raiola, Anna Maria, Di Grazia, Carmen, Gualandi, Francesca, Van Lint, Maria Teresa, Ferrara, Felicetto, Finizio, Olimpia, Angelucci, Emanuele, and Bacigalupo, Andrea

Published
2018
Full Text
View/download PDF

3. Thymoglobulin Prevents Chronic Graft-versus-Host Disease, Chronic Lung Dysfunction, and Late Transplant-Related Mortality: Long-Term Follow-Up of a Randomized Trial in Patients Undergoing Unrelated Donor Transplantation

Author

Bacigalupo, Andrea, Lamparelli, Teresa, Barisione, Giovanni, Bruzzi, Paolo, Guidi, Stefano, Alessandrino, Paolo Emilio, di Bartolomeo, Paolo, Oneto, Rosi, Bruno, Barbara, Sacchi, Nicoletta, van Lint, Maria Teresa, and Bosi, Alberto

Published
2006
Full Text
View/download PDF

4. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO)

Author

Bacigalupo, Andrea, Lamparelli, Teresa, Bruzzi, Paolo, Guidi, Stefano, Alessandrino, Paolo Emilio, di Bartolomeo, Paolo, Oneto, Rosa, Bruno, Barbara, Barbanti, Mario, Sacchi, Nicoletta, Van Lint, Maria Teresa, Bosi, Alberto, and for Gruppo Italiano Trapianti Midollo Osseo (GITMO)

Published
2001
Full Text
View/download PDF

5. Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow Transplantation

Author

Schmid, Christoph, primary, de Wreede, Liesbeth C., additional, van Biezen, Anja, additional, Finke, Jürgen, additional, Ehninger, Gerhard, additional, Ganser, Arnold, additional, Volin, Liisa, additional, Niederwieser, Dietger, additional, Beelen, Dietrich, additional, Alessandrino, Paolo, additional, Kanz, Lothar, additional, Schleuning, Michael, additional, Passweg, Jakob, additional, Veelken, Hendrik, additional, Maertens, Johan, additional, Cornelissen, Jan J., additional, Blaise, Didier, additional, Gramatzki, Martin, additional, Milpied, Noel, additional, Yakoub-Agha, Ibrahim, additional, Mufti, Ghulam, additional, Rovira, Montserrat, additional, Arnold, Renate, additional, de Witte, Theo, additional, Robin, Marie, additional, and Kröger, Nikolaus, additional

Published
2017
Full Text
View/download PDF

6. Long-term study on symptomless human metapneumovirus infection in hematopoietic stem cell transplant recipients

Author

Debiaggi, Maurizia, Canducci, Filippo, Terulla, Cristina, Sampaolo, Michela, Marinozzi, Maria Chiara, Alessandrino, Paolo Emilio, anna amelia colombo, Caldera, Daniela, Bragotti, Letizia Zenone, Migliavacca, Roberta, Bianchi, Emanuela, Romero, Egidio, Clementi, Massimo, Debiaggi, M, Canducci, F, Terulla, C, Sampaolo, M, Marinozzi, Mc, Alessandrino, Pe, Colombo, Aa, Caldera, D, Bragotti, Lz, Migliavacca, R, Bianchi, E, Romero, E, and Clementi, Massimo

Subjects
Adult, Cross Infection, Paramyxoviridae Infections, Reverse Transcriptase Polymerase Chain Reaction, Respiratory Tract Diseases, Hematopoietic Stem Cell Transplantation, Infant, Newborn, Infant, Polymerase Chain Reaction, Italy, Nasopharynx, Acute Disease, Carrier State, Prevalence, Humans, RNA, Viral, Longitudinal Studies, Metapneumovirus, Seasons, Sequence Analysis
Abstract

From October 2004 through October 2006 a study was performed to evaluate the prevalence of human Metapneumovirus (hMPV) infection in adult hematopoietic stem cell transplant (HSCT) recipients. Sequential nasopharyngeal aspirates (NPA) were collected independently from respiratory symptoms and evaluated for hMPV-RNA by polymerase chain reaction (PCR) and sequence analysis. Results indicate epidemiological and molecular differences between the 2004-2005 and 2005-2006 periods and that hMPV seems not to symptomatically affect HSCT patients or cause late respiratory sequelae. In addition, data collected suggest a hospital origin of hMPV infection in most HSCT patients during the 2004-2005 period.

Published
2007

7. WHO Classification and WPSS Score Predict Post-Transplant Outcome in Adults with Myelodysplastic Syndrome: A Retrospective Study by GITMO - Gruppo Italiano Trapianto Midollo Osseo.

Author

Alessandrino, Paolo E., primary, Della Porta, Matteo G., primary, Bacigalupo, Andrea, primary, Van Lint, Maria Teresa, primary, Falda, Michele, primary, Onida, Francesco, primary, Bernardi, Massimo, primary, Iori, Anna P., primary, Rambaldi, Alessandro, primary, Cerretti, Raffaella, primary, Marenco, Paola, primary, Pioltelli, Pietro, primary, Pascutto, Cristiana, primary, Oneto, Rosi, primary, Fanin, Renato, primary, and Bosi, Alberto, primary

Published
2007
Full Text
View/download PDF

8. Effect of HLA-Matching on Outcome of Hematopoietic Stem Cell Transplantation from Unrelated Donors: A IBMDR-GITMO Study.

Author

Crocchiolo, Roberto, primary, Ciceri, Fabio, additional, Oneto, Rosa, additional, Bruno, Barbara, additional, Pollichieni, Simona, additional, Sacchi, Nicoletta, additional, Sormani, Maria Pia, additional, Fanin, Renato, additional, Bandini, Giuseppe, additional, Bosi, Alberto, additional, Rambaldi, Alessandro, additional, Alessandrino, Paolo Emilio, additional, Falda, Michele, additional, and Bacigalupo, Andrea, additional

Published
2007
Full Text
View/download PDF

9. Allogeneic SCT with Matched Related and Unrelated Donors for Patients (pts) with Refractory Anemia (RA): Improved Survival after Introduction of Reduced Intensity Conditioning (RIC) Regimens.

Author

de Witte, T.M., primary, Brand, Ronald, additional, van Biezen, Anja, additional, Mufti, Ghulam, additional, Ruutu, Tapani, additional, Finke, Jurgen, additional, von dem Borne, Peter, additional, Vitek, Antonin, additional, Delforge, Michel, additional, Alessandrino, Paolo E., additional, Harhalakis, Nicholas, additional, Russell, Nigel H., additional, Carreras, Enric, additional, Verdonck, Leo F., additional, and Niederwieser, Dietger W., additional

Published
2006
Full Text
View/download PDF

10. Outcome of Patients with Primary Refractory Acute Myeloid Leukemia (AML) Undergoing Myeloablative Allogeneic Stem-Cell Transplantation (alloSCT) from HLA-Identical Sibling: Favorable Outcome in a Subset of Patients.

Author

Esteve, Jordi, primary, Labopin, Myriam, additional, Ehninger, Gerhard, additional, Fassas, Athanasios, additional, Finke, Jurgen, additional, Sanz, Miguel A., additional, Alessandrino, Paolo, additional, Fauser, Axel Arthur, additional, and Rocha, Vanderson, additional

Published
2006
Full Text
View/download PDF

11. Thrombotic Thrombocytopenic Purpura after Allogeneic Hematopoietic Stem Cell Transplantation: A Complication Still Frequent and Responsible of Severe Outcome.

Author

Uderzo, Cornelio, primary, Sangalli, Haidi, primary, Bonanomi, Sonia, primary, Morreale, Giuseppe, primary, Lanino, Edoardo, primary, Annaloro, Claudio, primary, Volpe, Aldo Della, primary, Alessandrino, Paolo, primary, Lazzarino, Mario, primary, Renoldi, Mila, primary, Ferrari, Paolo, primary, Iacobelli, Massimo, primary, Busca, Alessandro, primary, Locatelli, Franco, primary, Balduzzi, Adriana, primary, and Rovelli, Attilio, primary

Published
2005
Full Text
View/download PDF

12. Long Term Follow up of Two Randomized Trials on Antithymocyte Globulin (ATG) for GVHD Prophylaxis in Unrelated Donor Transplants: Chronic GVHD, Bronchiolitis and Quality of Life.

Author

Bacigalupo, Andrea, primary, Vignola, Maurizio, primary, Lamparelli, Teresa, primary, Bruzzi, Paolo, primary, Guidi, Stefano, primary, Alessandrino, Paolo, primary, Di Bartolomeo, Palo, primary, Oneto, Rosa, primary, Bruno, Barbara, primary, Barbanti, Mario, primary, Sacchi, Nicoletta, primary, Van Lint, Maria Teresa, primary, and Bosi, Alberto, primary

Published
2004
Full Text
View/download PDF

13. Allogeneic Bone Marrow Transplantation From HBsAg+Donors: A Multicenter Study From the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)

Author

Locasciulli, Anna, Alberti, Alfredo, Bandini, Giuseppe, Polchi, Paola, Arcese, William, Alessandrino, Paolo, Bosi, Alberto, Testa, Marina, and Bacigalupo, Andrea

Abstract

Hepatitis B virus (HBV)-infected individuals are occasionally used as donors for bone marrow transplantation (BMT). We studied the rate of HBV infection and the clinical expression of the associated liver disease in patients receiving marrow from HBsAg+donors. We performed a retrospective survey in 14 BMT units in Italy in which all BMTs performed between 1984 and 1994 were reviewed and those involving HBsAg+donors were identified. Donors and recipients were analyzed for HBV markers and liver disease. A total of 24 of 2,586 patients (0.9%) had received an HBsAg+marrow. HBsAg became detectable in 22% of pre-BMT HBsAg-patients, but only 5.5% became chronic HBsAg carriers. Anti-genemia developed more frequently in anti-HBs-compared with anti-HBs+patients independently of passive prophylaxis with hyperimmune anti-HBs Ig, although the difference was not significant. Severe liver failure with death occurred in 21% of patients, which was a value greater than that generally observed after BMT in our units (3.7%). Patients with an anti-HBe+donor had higher frequency of liver failure (28% v0%) and alanine aminotransferase peaks as compared with those of patients with an HBeAg+donor. Liver failure was not observed in anti-HBs+recipients. The use of HBsAg+donors, particularly if anti-HBe+, increases the risk of severe liver disease in BMT recipients. Anti-HBs positivity may prevent severe liver damage.

Published
1995
Full Text
View/download PDF

15. Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow Transplantation.

Author

Schmid C, de Wreede LC, van Biezen A, Finke J, Ehninger G, Ganser A, Volin L, Niederwieser D, Beelen D, Alessandrino P, Kanz L, Schleuning M, Passweg J, Veelken H, Maertens J, Cornelissen JJ, Blaise D, Gramatzki M, Milpied N, Yakoub-Agha I, Mufti G, Rovira M, Arnold R, de Witte T, Robin M, and Kröger N

Subjects
Adolescent, Adult, Aged, Allografts, Europe, Female, Humans, Lymphocyte Transfusion, Male, Middle Aged, Myelodysplastic Syndromes therapy, Recurrence, Registries, Reoperation, Retrospective Studies, Risk Factors, Treatment Outcome, Young Adult, Hematopoietic Stem Cell Transplantation methods, Leukemia, Myeloid, Acute etiology, Myelodysplastic Syndromes pathology
Abstract

No standard exists for the treatment of myelodysplastic syndrome relapsing after allogeneic stem cell transplantation. We performed a retrospective registry analysis of outcomes and risk factors in 698 patients, treated with different strategies. The median overall survival from relapse was 4.7 months (95% confidence interval: 4.1-5.3) and the 2-year survival rate was 17.7% (95% confidence interval: 14.8-21.2%). Shorter remission after transplantation ( P <0.001), advanced disease ( P =0.001), older age ( P =0.007), unrelated donor ( P =0.008) and acute graft- versus -host disease before relapse ( P <0.001) adversely influenced survival. At 6 months from relapse, patients had received no cellular treatment, (i.e. palliative chemotherapy or best supportive care, n=375), donor lymphocyte infusion (n=213), or a second transplant (n=110). Treatment groups were analyzed separately because of imbalanced characteristics and difficulties in retrospectively evaluating the reason for individual treatments. Of the patients who did not receive any cellular therapy, 109 were alive at 6 months after relapse, achieving a median overall survival from this landmark of 8.9 months (95% confidence interval: 5.1-12.6). Their 2-year survival rate was 29.7%. Recipients of donor lymphocytes achieved a median survival from first infusion of 6.0 months (95% confidence interval: 3.7-8.3) with a 2-year survival rate of 27.6%. Longer remission after first transplantation ( P <0.001) and younger age ( P =0.009) predicted better outcome. Among recipients of a second transplant, the median survival from second transplantation was 4.2 months (95% confidence interval: 2.5-5.9), and their 2-year survival rate was 17.0%. Longer remission after first transplantation ( P <0.001), complete remission at second transplant ( P =0.008), no prior chronic graft- versus -host disease ( P <0.001) and change to a new donor ( P =0.04) predicted better outcome. The data enabled identification of patients benefiting from donor lymphocyte infusion and second transplantation, and may serve as a baseline for prospective trials., (Copyright© 2018 Ferrata Storti Foundation.)

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results